Repligen (RGN) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGN Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Repligen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGN Stock 12 Month Forecast

Average Price Target

€157.53

▲(4.88% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is €157.53 with a high forecast of €195.10 and a low forecast of €125.73. The average price target represents a 4.88% change from the last price of €150.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"93":"€93","196":"€196","118.75":"€118.8","144.5":"€144.5","170.25":"€170.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":195.10418475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€195.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":157.52856398333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€157.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125.73380795,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€125.73</span>\n  </div></div>","useHTML":true}}],"tickPositions":[93,118.75,144.5,170.25,196],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.65,157.76186036538462,160.87372073076924,163.98558109615385,167.09744146153847,170.20930182692308,173.3211621923077,176.4330225576923,179.54488292307693,182.65674328846154,185.76860365384616,188.88046401923077,191.9923243846154,{"y":195.10418475,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.65,154.87142799871796,155.09285599743592,155.31428399615385,155.5357119948718,155.75713999358976,155.97856799230772,156.19999599102565,156.4214239897436,156.64285198846156,156.86427998717951,157.08570798589744,157.3071359846154,{"y":157.52856398333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.65,152.4256775346154,150.20135506923077,147.97703260384617,145.75271013846154,143.52838767307694,141.3040652076923,139.0797427423077,136.85542027692307,134.63109781153847,132.40677534615384,130.18245288076923,127.95813041538462,{"y":125.73380795,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":102.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.7,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.65,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€195.10

Average Price Target€157.53

Lowest Price Target€125.73

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Daniel Arias

Stifel Nicolaus

―

Buy

―

Reiterated

09/15/26

Repligen (RGEN) Gets a Buy from Stifel Nicolaus

Doug Schenkel

UBS

€169.09→€195.1

Buy

29.90%

Upside

Reiterated

09/09/26

Repligen assumed with a Buy at UBSRepligen assumed with a Buy at UBS

Evan Stampler

Wells Fargo

€156.08→€160.42

Buy

6.80%

Upside

Reiterated

08/16/26

Wells Fargo Keeps Their Buy Rating on Repligen (RGEN)

Casey Woodring

J.P. Morgan

€143.08→€151.75

Buy

1.03%

Upside

Assigned

07/29/26

Repligen price target raised to $175 from $165 at JPMorganRepligen price target raised to $175 from $165 at JPMorgan

Brendan Smith

TD Cowen

€173.43

Buy

15.46%

Upside

Reiterated

07/28/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Dan Leonard

RBC Capital

€138.74→€160.42

Buy

6.80%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN) and Envista Holdings (NYSE: NVST)

Matt Larew

William Blair

―

Buy

―

Reiterated

07/28/26

Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength

Kyle Mikson CFA

Canaccord Genuity

€125.73

Hold

-16.29%

Downside

Reiterated

07/28/26

Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target

Luke Sergott

Barclays

€138.74→€151.75

Buy

1.03%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (Other OTC: SEMHF) and Repligen (NASDAQ: RGEN)

Robert Wasserman

Benchmark Co.

€160.42

Buy

6.80%

Upside

Upgraded

07/07/26

Repligen upgraded to Buy from Hold at BenchmarkRepligen upgraded to Buy from Hold at Benchmark

Daniel Markowitz CFA

Evercore ISI

€130.07→€138.74

Buy

-7.63%

Downside

Reiterated

07/06/26

Repligen price target raised to $160 from $150 at Evercore ISIRepligen price target raised to $160 from $150 at Evercore ISI

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

06/24/26

Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)

Yessica Sanchez Gudino

HSBC

€147.41→€130.07

Buy

-13.40%

Downside

Reiterated

06/03/26

Repligen price target lowered to $150 from $170 at HSBCRepligen price target lowered to $150 from $170 at HSBC

Michael Polark

Wolfe Research

€125.73

Buy

-16.29%

Downside

Initiated

06/01/26

Repligen assumed with an Outperform at Wolfe ResearchRepligen assumed with an Outperform at Wolfe Research

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

05/07/26

Guggenheim Reaffirms Their Hold Rating on Repligen (RGEN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Daniel Arias

Stifel Nicolaus

―

Buy

―

Reiterated

09/15/26

Repligen (RGEN) Gets a Buy from Stifel Nicolaus

Doug Schenkel

UBS

€169.09→€195.1

Buy

29.90%

Upside

Reiterated

09/09/26

Repligen assumed with a Buy at UBSRepligen assumed with a Buy at UBS

Evan Stampler

Wells Fargo

€156.08→€160.42

Buy

6.80%

Upside

Reiterated

08/16/26

Wells Fargo Keeps Their Buy Rating on Repligen (RGEN)

Casey Woodring

J.P. Morgan

€143.08→€151.75

Buy

1.03%

Upside

Assigned

07/29/26

Repligen price target raised to $175 from $165 at JPMorganRepligen price target raised to $175 from $165 at JPMorgan

Brendan Smith

TD Cowen

€173.43

Buy

15.46%

Upside

Reiterated

07/28/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Dan Leonard

RBC Capital

€138.74→€160.42

Buy

6.80%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN) and Envista Holdings (NYSE: NVST)

Matt Larew

William Blair

―

Buy

―

Reiterated

07/28/26

Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength

Kyle Mikson CFA

Canaccord Genuity

€125.73

Hold

-16.29%

Downside

Reiterated

07/28/26

Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target

Luke Sergott

Barclays

€138.74→€151.75

Buy

1.03%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (Other OTC: SEMHF) and Repligen (NASDAQ: RGEN)

Robert Wasserman

Benchmark Co.

€160.42

Buy

6.80%

Upside

Upgraded

07/07/26

Repligen upgraded to Buy from Hold at BenchmarkRepligen upgraded to Buy from Hold at Benchmark

Daniel Markowitz CFA

Evercore ISI

€130.07→€138.74

Buy

-7.63%

Downside

Reiterated

07/06/26

Repligen price target raised to $160 from $150 at Evercore ISIRepligen price target raised to $160 from $150 at Evercore ISI

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

06/24/26

Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)

Yessica Sanchez Gudino

HSBC

€147.41→€130.07

Buy

-13.40%

Downside

Reiterated

06/03/26

Repligen price target lowered to $150 from $170 at HSBCRepligen price target lowered to $150 from $170 at HSBC

Michael Polark

Wolfe Research

€125.73

Buy

-16.29%

Downside

Initiated

06/01/26

Repligen assumed with an Outperform at Wolfe ResearchRepligen assumed with an Outperform at Wolfe Research

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

05/07/26

Guggenheim Reaffirms Their Hold Rating on Repligen (RGEN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARWRArrowhead Pharmaceuticals

PTGXProtagonist Therapeutics

ESTAEstablishment Labs Holdings

ZVRAZevra Therapeutics

IMUXImmunic

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

3 Months

Luke SergottBarclays

Success Rate

7/9 ratings generated profit

Average Return

+7.57%

Copying Luke Sergott's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +7.57% per trade.

1 Year

Luke SergottBarclays

Success Rate

9/9 ratings generated profit

Average Return

+18.57%

Copying Luke Sergott's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.57% per trade.

2 Years

Luke SergottBarclays

Success Rate

9/9 ratings generated profit

Average Return

+22.93%

Copying Luke Sergott's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +22.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGN Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGN has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RGN average Analyst price target in the past 3 months is 157.53.

Each month's total comprises the sum of three months' worth of ratings.

RGN Financial Forecast

RGN Earnings Forecast

Next quarter’s earnings estimate for RGN is €0.40 with a range of €0.35 to €0.42. The previous quarter’s EPS was €0.46. RGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RGN has Performed in-line its overall industry.

RGN Sales Forecast

Next quarter’s sales forecast for RGN is €177.80M with a range of €176.24M to €178.99M. The previous quarter’s sales results were €175.49M. RGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RGN has Performed in-line its overall industry.

RGN Stock Forecast FAQ

What is DE:RGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Repligen Corp’s 12-month average price target is 157.53.

What is DE:RGN’s upside potential, based on the analysts’ average price target?

Repligen Corp has 4.88% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Repligen Corp a Buy, Sell or Hold?

Repligen Corp has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Repligen Corp’s share price target?

The average share price target for Repligen Corp is 157.53. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €195.10 ,and the lowest forecast is €125.73. The average share price target represents 4.88% Increase from the current price of €150.2.

What do analysts say about Repligen Corp?

Repligen Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Repligen Corp?

To buy shares of DE:RGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Repligen (RGN) Stock Forecast & Price Target

RGN Analyst Ratings

RGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Repligen

RGN Analyst Recommendation Trends

RGN Financial Forecast

RGN Earnings Forecast

RGN Sales Forecast

RGN Stock Forecast FAQ

Detailed List of Analyst Forecasts